Everest Medicines Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	851.28	706.68	125.93	12.79	0.05	-
Revenue Growth (YoY)	103.39%	461.16%	884.46%	23588.89%	-	-
Cost of Revenue	254.08	177.79	34.41	4.65	0.02	-
Gross Profit	597.21	528.89	91.52	8.15	0.03	-
Selling, General & Admin	896.3	758.15	396.57	603.23	440.83	311.08
Research & Development	470.1	528.04	540.05	809.74	613.43	377.41
Other Operating Expenses	-43.02	22.92	6.16	-0.12	-4.96	-0.98
Operating Expenses	1,323	1,309	942.78	1,413	1,049	687.51
Operating Income	-726.17	-780.21	-851.27	-1,405	-1,049	-687.51
Interest Expense	-22.9	-22.19	-23.06	-5.59	-4.81	-33.87
Interest & Investment Income	74.46	95.21	107.67	38.48	28.88	2.04
Currency Exchange Gain (Loss)	14.95	19.51	-28.07	-155.18	22.94	-0.85
Other Non Operating Income (Expenses)	-2.46	2.65	2.82	-1.61	-6.46	-4,938
EBT Excluding Unusual Items	-662.12	-685.03	-791.91	-1,529	-1,009	-5,658
Gain (Loss) on Sale of Investments	-0.01	-0.01	0.85	-21.75	-	-
Gain (Loss) on Sale of Assets	-0.03	-	-1.43	1,320	-	-
Asset Writedown	-	-356.34	-51.97	-16.49	-	-
Other Unusual Items	3.41	-	-	-	-	-
Pretax Income	-658.75	-1,041	-844.46	-247.28	-1,009	-5,658
Income Tax Expense	-	-	-	0.01	-	-
Net Income	-658.75	-1,041	-844.46	-247.28	-1,009	-5,658
Net Income to Common	-658.75	-1,041	-844.46	-247.28	-1,009	-5,658
Shares Outstanding (Basic)	323	321	313	298	293	85
Shares Outstanding (Diluted)	323	321	313	298	293	85
Shares Change (YoY)	0.25%	2.51%	5.18%	1.49%	243.61%	1532.82%
EPS (Basic)	-2.04	-3.24	-2.70	-0.83	-3.44	-66.29
EPS (Diluted)	-2.04	-3.24	-2.70	-0.83	-3.44	-66.29
Free Cash Flow	-487.68	-744.92	-886.53	-1,512	-839.89	-480.5
Free Cash Flow Per Share	-1.51	-2.32	-2.83	-5.08	-2.86	-5.63
Gross Margin	70.15%	74.84%	72.67%	63.69%	57.41%	-
Operating Margin	-85.30%	-110.41%	-675.97%	-10981.12%	-1943096.30%	-
Profit Margin	-77.38%	-147.36%	-670.57%	-1933.11%	-1867998.15%	-
Free Cash Flow Margin	-57.29%	-105.41%	-703.97%	-11817.36%	-1555344.44%	-
EBITDA	-594.67	-670.04	-795.72	-1,391	-1,043	-683.03
EBITDA Margin	-69.86%	-94.82%	-	-	-	-
D&A For EBITDA	131.5	110.17	55.55	13.81	6.21	4.48
EBIT	-726.17	-780.21	-851.27	-1,405	-1,049	-687.51
EBIT Margin	-85.30%	-110.41%	-	-	-	-

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.